Unió Europea - anglès - EMA (European Medicines Agency)

rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - melatonin neurim is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.

Irlanda - anglès - HPRA (Health Products Regulatory Authority)

pharma nord aps - melatonin - film-coated tablet - 3 milligram(s) - melatonin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate; lactose monohydrate; colloidal anhydrous silica; purified talc; magnesium stearate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

pharma nord aps - melatonin 3 mg - film-coated tablet - 3 mg - melatonin 3 mg - melatonin

Bèlgica - anglès - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

aurobindo sa-nv - melatonin 2 mg - prolonged-release tablet - 2 mg - melatonin 2 mg - melatonin

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - melatonin, quantity: 2 mg - tablet, modified release - excipient ingredients: lactose monohydrate; magnesium stearate; purified talc; colloidal anhydrous silica; ammonio methacrylate copolymer; calcium hydrogen phosphate dihydrate - monotherapy for the short term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - caffeine, quantity: 20 mg - injection, intravenous infusion - excipient ingredients: sodium citrate dihydrate; water for injections; citric acid monohydrate - cafnea injection is indicated for the short-term treatment of apnoea of prematurity in infants between 28 and 33 weeks gestational age.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - furosemide sodium, quantity: 10.664 mg/ml (equivalent: furosemide, qty 10 mg/ml) - injection, solution - excipient ingredients: water for injections; sodium chloride; sodium hydroxide - oedema: lasix is indicated in adults, infants and children for the treatment of oedema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. lasix is particularly useful when an agent with greater diuretic potential than that of those commonly employed is desired. parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. lasix injection is also indicated as adjunctive therapy in acute pulmonary oedema and cerebral oedema where intense and rapid onset of diuresis is desired. if gastrointestinal absorption is impaired or oral medication is not practical for any reason, lasix is indicated by the intravenous route. parenteral use should be replaced with oral lasix as soon as practical.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetylcysteine, quantity: 6 g - injection - excipient ingredients: sodium hydroxide; water for injections - as an antidote for paracetamol poisoning: acetadote injection is indicated in the treatment of paracetamol overdose to protect against hepatoxicity.

Austràlia - anglès - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - fluconazole, quantity: 200 mg - injection, solution - excipient ingredients: sodium chloride; water for injections - fluconazole injection is indicated for the following conditions but should be used only when fluconazole cannot be administered orally: 1. treatment of cryptococcal meningitis in patients who are unable to tolerate amphotericin b. note: data suggest that the clinical efficacy of fluconazole is lower than that of amphotericin b in the treatment of the acute phase of cryptococcal meningitis. 2. maintenance therapy to prevent relapse of cryptococcal meningitis in patients with acquired immune deficiency syndrome (aids). 3. treatment of oropharyngeal and oesophageal candidiasis in patients with aids and other immunosuppressed patients. 4. secondary prophylaxis of oropharyngeal candidiasis in patients with human immunodeficiency virus (hiv) infection. 5. serious and life-threatening candida infections in patients who are unable to tolerate amphotericin b. note: it remains to be shown that fluconazole is as effective as amphotericin b in the treatment of serious and life-threatening candida infections. until such data are available, amphotericin b remains the drug of choice.